Recruiting Heart Attack Studies in Riverside
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to severe symptoms. The main questions it aims to answer ar...
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA)....
About Heart Attack Clinical Trials in Riverside
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 2 heart attack clinical trials recruiting participants in Riverside, CA. These studies are seeking a combined 531 participants. Research is being sponsored by Viatris Innovation GmbH, Janssen Research & Development, LLC. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in Riverside — FAQ
Are there heart attack clinical trials in Riverside?
Yes, there are 2 heart attack clinical trials currently recruiting in Riverside, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Riverside?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Riverside research site will contact you about next steps.
Are clinical trials in Riverside free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Riverside studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 2 active trials in Riverside are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov